Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Kidney and Urological Diseases Drug Data - A-Z (English)
Drug Class Description
Antiseptics.Generic Name
Povidone-iodine - vaginal infectionsDrug Description
Povidone Iodine USP 10% w/v.Presentation
Solution.Indications
As a vaginal cleanser in the treatment of vaginitis due to candidal, trichomonal, non-specific or mixed infections and for pre-operative preparation of the vagina.Adult Dosage
For intravaginal use. Adults and the elderly: Once a day (preferably in the morning) for a 14 day period, including days of menstruation. The Betadine VC Concentrate should be diluted 1:10 using the measuring cap, and used according to the patient instruction leaflet provided. The applicators should only be used for the administration of the diluted VC Kit solution. This product may be used in combination with Betadine Vaginal Pessaries. Children: Contra-indicated for use in pre-pubertal children.
Child Dosage
Not applicable.Contra Indications
Known or suspected iodine hypersensitivity. Regular use is contra-indicated in patients and users with thyroid disorders (in particular nodular colloid goitre, endemic goitre and Hashimoto's thyroiditis).
Special Precautions
Special caution is needed when regular applications to broken skin are made to patients with pre-existing renal insufficiency. Regular use should be avoided in patients on concurrent lithium therapy.
Interactions
Absorption of iodine from povidone iodine through either intact or broken skin may interfere with thyroid function tests. Contamination with povidone iodine of several types of tests for the detection of occult blood in faeces or blood in urine may produce false-positive results.
Adverse Reactions
If local irritation, redness or swelling develops, discontinue treatment. Iodine is absorbed from the vagina and following prolonged use, thyroid dysfunction may develop. The product may be spermicidal and should not be used when conception is desired.
Manufacturer
Molnlycke Health CareDrug Availability
(P)Updated
09 April 2009Advert for Healthcare Professionals Only
Related News
Toviaz(Pfizer) success in Overactive Bladder in Older Patients Kidney and Urological Diseases Page
Toviaz (fesoterodine fumarate) from Pfizer has met its primary endpoint in Study A0221049.This was a 12 week trial which enrolled 562 patients aged 65 or older who were randomised to either fesoterodine or placebo. Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urgency urinary incontinence episodes per day at the end of treatment for Overactive Bladder. While the prevalence of overactive bladder increases with age, limited research has been conducted in older individuals with this condition. Toviaz, a muscarinic antagonist, is approved in both the USA and EU to treat the symptoms of Overactive Bladder.
FDA approves Anturol (Watson Pharma) for Overactive Bladder treatment Kidney and Urological Diseases Page
FDA has approved Anturol (oxybutynin) from Antares Pharma/Watson Pharma as a topical gel 3% for the treatment of Overactive Bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. The active ingredient is delivered transdermally, and not metabolized by the liver in the same way as orally administered oxybutynin. This results in a low level of side effects, such as dry mouth and constipation. Under an exclusive licensing agreement, Watson anticipates launching the product in 2012.
